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Role of mir-33a, mir-203b, mir361-3p, and mir-424 in hepatocellular carcinoma
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Background/aim: Hepatocellular carcinoma (HCC) is one of the most aggressive cancer types. MicroRNAs (miRNAs) are small
noncoding regulatory RNAs that function posttranscriptionally. miRNA deregulation was observed in the development and progression
of HCC. In this study, we aimed to investigate the expression levels of four miRNAs (mir-33a, mir-203b, mir361-3p, and mir-424) in
HCC patients in comparison to healthy individuals.
Materials and methods: Venous blood samples were collected from both HCC patients and healthy individuals. In order to determine
the relative expression levels of mir-33a, mir-203b, mir361-3p, and hsa-mir-424 in HCC patients, probe-based quantitative real time
PCR (qRT-PCR) was performed. The cycle threshold (Ct) results were analyzed according to the 2−∆∆Ct method and statistical analyses
were performed by SPSS Statistics version 15 for Windows.
Results: qRT-PCR analysis revealed that the expression levels of mir-33a (fold change: 7.3 and P < 0.001), mir-203b (fold change: 4.6
and P < 0.001), and mir361-3p (fold change: 5.1 and P < 0.001)were downregulated compared to healthy individuals and mir-424 did
not show any significant change between HCC patients and controls.
Conclusion: Our results indicated that mir-33a, mir-203b, and mir-361-3p may significantly contribute to tumor pathogenesis in HCC
and have potential to be used as a noninvasive biomarker for cancer therapy.
Key words: Mir-33a, mir-203b, mir361-3p, mir-424, HCC, qRT-PCR

1. Introduction
HCCis the leading cause of cancer-related deaths
worldwide. It is caused by hepatocytes and it is one of the
most frequently diagnosed types of primary liver cancer,
constituting 80%–90% of primary liver tumors [1,2].
Infection with chronic viral hepatitis B and hepatitis C is
the leading etiological factor for developing HCC. It has
many different risk factors including hereditary, exposure
to chemical agents such as aflatoxin B1, smoking, and
chronic alcohol abuse [3]. miRNAs are single-stranded,
small noncoding post transcriptional regulator RNAs that
are comprised of ~20 nucleotides and have an important
role cancer progression [4].
The analysis of miRNA expression levels in blood
provides critical information about the prognosis of the
diseasessuch as cancer and monitoring of treatment.
The analysis of tissue-specific miRNA expression level
can both detect tumor origin and allow early diagnosis

of carcinogenesis. Numerous studies have shown that
circulating miRNAs have clinical importance as diagnostic
and prognostic biomarkers in HCC [5–7].
mir-33a is a highly conserved member of mir-33,
which is located in the intronic region. It plays a role in
lipid metabolism and provides glucose and cholesterol
regulation. miR-33a has been shown to have growth,
apoptosis, epithelial-mesenchymal transition, and tumor
suppressor effects on cancer cells [8].
mir-203 serves as a tumor suppressor in many types
of cancer including hepatocellular carcinoma, prostate,
esophageal cancers, and breast cancer. miR-203 has been
reported to play an important role in the carcinogenesis
and progression of HCC, and there are also studies
suggesting that miR-203 may be a prognostic factor in
HCC [9,10].
The effects of miR‐361‐3p on proliferation, invasion,
migration, and colony formation have been reported.
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A study has indicated that mir-361-3p, which has been
shown to play an active role in body fluids, decreases the
levels of expression in prostate secretion in prostate cancer
patients[11].
mir-424, which has been found to have decreased
expression in many cancer types, has been reported to
play a role as tumor suppressor. It has been found to
induce cell migration and play an important role in cancer
development and progression in HCC [5].
In the literature, the expression levels of mir-33a, mir203b, mir361-3p, and mir-424 have been reported to be
either increased or decreased in various malignancies. A
limited number of studies have reported these circulating
miRNAs in cancer types.
The current study examined for the first time the
expression levels of mir-33a, mir-203b, mir361-3p, and
mir-424 of peripheral blood serum in order to determine
the potential biomarkers for early diagnosis, treatment, and
prognosis in HCC.
2. Materials and methods
2.1. Sample collection
Venous blood samples were collected from 34 patients who
were admitted to the Gastroenterology Outpatient Clinicin
Haydarpaşa Numune Training and Research Hospital of
the University of Health Sciences and İstanbul University
Oncology Institute. They had been newly diagnosed with
HCC and the patients who agreed to participate in the study
were over the age of 18. The patients who were not included
in the study were those who had received radiotherapy
and chemotherapy,thecases with confirmed infection and
chronic inflammatory diseases as well as those with tumors
in another organ, and those who used antibiotics and
antiinflammatory drugs and corticosteroids.
As the control group, blood samples were obtained
from healthy individuals who were not related to any type
of cancer. All venous blood samples were centrifuged at
3000 rpm for 10 min and the extracted serum samples were
stored in a freezer at −80 °C.
Drinking status, smoking status, and family history
of cancer were recorded according to the declarations of
patients and healthy individuals. The presence of chronic
hepatitis B and C and cirrhosis was recorded according to
laboratory and radiological test results. All epidemiologic
variables and clinical data were collected by physicians
(Table 1).
2.2. RNA isolation
RNAs were isolated from 500 µL fresh serum samples with
a mirVana™ miRNA Isolation Kit (Thermo Fisher Scientific,
Waltham, MA, USA; Catalog No AM1560) according to the
manufacturer’s protocol. The concentration and purity of
the isolated RNAs were measured at 230, 260, and 280 nm
with a NanoDrop Spectrophotometer (ND-1000 Thermo
Fisher Scientific).

2.3. Reverse transcription and real time quantification of
miRNA expression
From each sample of HCC patients and healthy
individuals, 20 ng of total RNA was reverse‐transcribed to
cDNA using specific miRNA TaqMan Assays and TaqMan
MicroRNA Reverse Transcription Kit (Cat no: 4366596,
Thermo Fisher Scientific) according to the manufacturer’s
protocol[12]. TaqMan MicroRNA Assays hsa‐miR‐33a,
hsa‐miR-203b, hsa‐miR-361-3p, hsa‐miR-424, and
RNU6B (Cat No: PN4427975) were obtained from Applied
Biosystems Thermo Fisher Scientific. RNU6B was used for
endogenous control of miRNA expression analyses.
The relative expression levels of miR‐33a, miR-203b,
miR-361-3p, and miR-424 were evaluated with qRT‐
PCR using TaqMan Universal PCR Master Mix (Cat no:
4364338, Thermo Fisher Scientific) with LightCycler 480
(Roche Applied Science, Penzberg, Germany).
The RT‐qPCR was performed as follows: 1 cycle of
95 °C for 5 min, followed by 40 cycles of 95 °C for 10 s,
60 °C for 20 s, and 72 °C for 25 s. All the samples were
run in duplicate. The relative quantification analysis was
performed by the delta‐delta‐Ct method as described
previously [13,14].
2.4. Statistical analysis
All the data were analyzed using SPSS Statistics version
15 for Windows. Two-sided Student’s t-test was used to
determine the significance of the difference between
the expression levels of the analyzed microRNAs. The
threshold P value <0.05 was considered of statistical
significance [13].Online tools were used for analyzing
the power of the microRNAs in distinguishing HCC
patients from healthy individuals and receiver operating
characteristic (ROC) curves plotted [15].
3. Results
Table 1 presents the epidemiologic variables and clinical
data of HCC patients and healthy individuals.
The mean female patient age was 51 ± 9 and 29% and
41% of the healthy individuals were female with a mean
age of 48 ± 10 years. More patients had a family history
of cancer than healthy individuals (P < 0.05), which was
determined as 32% and 12%, respectively.
In patients, 24% were ever smoker and 21% of them
were ever drinker. In healthy individuals, 32% were ever
smoker and 12% of them were ever drinker. As expected,
most of the patients (71%) had cirrhosis and 41% had
chronic hepatitis B, and 32% had chronic hepatitis C. None
of the healthy individuals had chronic hepatitis B or C;
also, none of them had cirrhosis. There was no significant
difference between patients and healthy individuals in
terms of sex, age, smoking, and drinking status (all P >
0.05).
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Table 1. Epidemiologic variables and clinical data of HCC patients and healthy
individuals.
Epidemiologic variables/
Clinical data

Patients
(n = 34, %)

Control
(n = 34, %)

P value

Age (years) (mean ± SD)

51 ± 9

48 ± 10

P > 0.05

Female/male

10(29)/24 (71)

14 (41)/20 (59)

P > 0.05

11 (32)

4 (12)

P < 0.05

Never

27 (79)

30 (88)

P > 0.05

Ever

7 (21)

4 (12)

P > 0.05

Never

26 (76)

23 (68)

P > 0.05

Ever

8 (24)

11 (32)

P > 0.05

Yes

24 (71)

-

Chronic hepatitis B

14 (41)

-

Chronic hepatitis C

11 (32)

-

<5 cm

24 (71)

-

≥5 cm

10(29)

-

I+II

22 (65)

-

III+IV

12 (35)

-

<100

26 (76)

-

≥100

8 (24)

-

Family history of cancer
Yes
Drinking status

Smoking status

Cirrhosis

Tumor size

TNM stage

α-fetoprotein (ng/mL)

The relative expression levels of cell-free miR‐33a, miR203b, miR-361-3p, and miR-424 from serum samples were
evaluated with RT‐qPCR. The Δ-ΔCt analysis of the RT‐
qPCR data showed that mir-33a was 7.3-fold less expressed
in HCC patients in comparison to healthy individuals (P =
0.000002), and mir-203b was less expressed like mir-33a.It
was determined that mir-33a decreased 4.6-fold in patients
when compared to the control group. Also, mir361-3p was
5.1-fold less expressed in patients than healthy individuals
(P = 0.000032). These results indicated that the relative
mir-33a, mir-203b, and mir361-3p expression levels were
significantly decreased in HCC patients in comparison to
the control group (P < 0.05) (Figures 1A–1C). When the
RT‐qPCR data of mir-424 were evaluated, it was shown
that there was not any significant change between the
patient and control group (Figure 1D).
When the RT‐qPCR results were compared, it was
found that the miRNA of some HCC patients had more
significant expression levels than other patients. It was
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found that the expression levels of mir361-3p and mir424 were significantly decreased in female HCC patients
in comparison to male HCC patients. Also, chronic
hepatitis B and smoking were upregulated, and cirrhosis
was downregulated compared to the other HCC patients
(P < 0.05) (Table 2).
We plotted ROC curves for analyzing the power of the
microRNAs in distinguishing HCC patients from healthy
individuals. It was found that mir361-3p had the highest
area under curve (AUC; 0.848), while mir-33a, mir-203b,
and mir-424 had AUC values of 0.847, 0.83, and 0.43,
respectively, in comparison to healthy individuals (Figures
2A–2D).
4. Discussion
In this study, we demonstrated that mir-33a, mir-203b,
mir361-3p, and mir-424 had variable but significantly
reduced expression levels compared to HCC tumor
samples and healthy control serum. It is thought that the
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Figure 1. A. Expression of mir-33a between HCC patients
(cancer) and the control group. B. Expression of mir-203 between
the cancer and the control group. C. Expression of mir361-3p
between the cancer and the control group. D. Expression of mir424 between the cancer and the control group. ***; P < 0.001.

causes of different miRNA expression profiles in cancer
patients may be passive or active release of miRNAs by
tumor cells. The expression levels of these 4 miRNAs in the
serum of HCC patients were observed to be significantly
reduced. It is known that miRNAs in body fluids can
survive without degradation for a long time and are not
affected by changing pH and temperature levels [16].
miR-33a plays a crucial role in regulation of
cholesterol metabolism and cellular phenotypes
associated with carcinoma progress. miR-33a suppresses
cell proliferation and metastasis of some cancer types by
targeting oncogenes [17,18]. Downregulation of miR-33a
activity in HCC increases the proliferative and invasive
potential of HCC cells. The data obtained from the study
also show that miR-33a plays a tumor suppressor role
in HCC. The mean 7.3-fold decrease in miR-33a was
observed in HCC patients.
Studies show that miRNA-203 acts as a tumor
suppressor in various types of cancer. It was shown that
mir-203 has a critical role in cell proliferation and invasion

in prostate carcinoma [19]. Also, it was demonstrated
that mir-203 expression levels were significantly lower in
colorectal cancer tissues in comparison to nontumor tissues
and it has overexpression in ovarian cancer [9,20]. These
results show that the expression levels of mir-203 differ in
each carcinoma. Our results show that mir-203 expression
levels decreased 4.6-fold in patients in comparison to the
control group. The results show similarity with colorectal
carcinoma.
The effects of mir361‐3p on proliferation, invasion,
migration, and colony formation have been reported.
mir361-3p, which plays an active role in body fluids, has
been shown to decrease the levels of expression in prostate
secretion in prostate cancer patients. Chen et al. reported
that mir361-3p is upregulated in NSCLC and it was shown
that it inhibits cell proliferation, migration, and invasion
[11]. Another study indicated that the overexpression
of mir361-5p suppresseslung cancer proliferation and
invasion and it acts as a tumor suppressor in lung cancer
[21]. Our results show that mir361‐3p was downregulated
and decreased 5.1-fold in patients in comparison to the
control group.
A decreased expression of mir-424 has been shown
in HCC cell lines and primary tumors, while decreased
mir-424 has been reported to accelerate cell proliferation,
migration, and invasion. In addition, the significant role
of c-Myb, an important invasive molecule in HCC, is a
direct target of mir-424 in tumorigenesis [5]. In our study,
there is no significant expression level of mir-424 in serum
samples obtained from HCC patients in comparison to
healthy individuals.
There are significant sex differences in the risks and
outcomes of cancer between females and males [22]. Our
study showed that there are differences in microRNA
(miRNA) expression in adult male and female HCC
patients. The expression levels of mir361-3p and mir424 were significantly decreased in female patients in
comparison to male patients. Also, drinking and smoking
status, chronic hepatitis B, and cirrhosis were significantly
associated with circulating miRNA expression [6].
According to our results, there is no correlation with the
expression levels of mir-203b, mir361-3p, and mir-424 in
patients withchronic hepatitis C. However,the expression
levels of mir-33a, mir-203b, mir361-3p, and mir-424
were decreased in patients with chronic hepatitis B. It was
shown that mir-33a, mir-203b, mir361-3p, and mir-424
were upregulated in smokers, and mir-203b and mir3613p were downregulated in cirrhosis patients compared to
other HCC patients. Despite these results, when all data of
HCC patients were compared with healthy individuals, it
was obvious that mir-33a, mir-203b, and mir361-3p were
less expressed (P < 0.05).
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Table 2. Fold change in expression levels of miRNAs with epidemiological status of HCC patients.
Patients/
healthy
individuals

HCC patients
Male/female

Hepatitis B
yes/no

Hepatitis C
yes/no

Smoking
yes/no

Drinking
yes/no

Cirrhosis
yes/no

Family history
of cancer yes/no

Mir-33a

7.3↓*

↔

2 ↓*

1.3 ↓*

2.8 ↓*

↔

↔

↔

Mir-203b

4.6 ↓*

↔

2 ↓*

↔

2.6 ↓*

↔

1.2 ↑*

↔

Mir361-3p

5.1 ↓*

1.6 ↓*

↔

3.7 ↓*

↔

1.7 ↑*

↔

Mir-424

↔

1.1 ↓*

↔

2.4 ↓*

↔

↔

↔

2.2 ↓*
1.9 ↓*

*; P < 0.05; ↑, upregulate; ↓, downregulate; ↔, no difference.

Figure 2. A. Receiver operating characteristic (ROC) analysis curve of mir-33a between HCC patients (cancer) and the control group. B.
ROC curve of mir-203 between the cancer and the control group. C. ROC curve of mir361-3p between the cancer and the control
group. D. ROC curve of mir-424 between the cancer and the control group. Curves to see the power of miRNAs in distinguishing HCC
patients from healthy individuals.

The ROC curve results of mir361-3p, mir-33a,
and mir-203b show that they are sufficient to have
the power to differentiate HCC patients from healthy
individuals. Since the AUC value of mir-414 was 0.43, it
was determined that there was no significant difference
between the groups.
5. Conclusion
In conclusion, this was the first study that examined the
expression levels of mir-33a, mir-203b, mir361-3p, and
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mir-424 of peripheral blood serum in order to determine
potential biomarkers for early diagnosis, treatment, and
prognosis in HCC. It was determined that mir-33a (fold
change: 7.3 and P < 0.001), mir-203b (fold change: 4.6 and
P < 0.001), and mir361-3p (fold change: 5.1 and P < 0.001)
was less expressed than healthy individuals and mir-424
did not show any significant change between the patient
and control group. mir-33a, mir-203b, and mir3613pmaypotentially be used as noninvasive biomarkers for
HCC diagnosis and treatment in the future.
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